Allogeneic Stem Cell Transplantation Offers Superior Outcomes in Chronic Myelomonocytic Leukemia

Strategic Insights -

Researchers at the Mayo Clinic have conducted a retrospective analysis of 138 patients with chronic myelomonocytic leukemia (CMML) who underwent allogeneic stem cell transplantation (ASCT). The study found that patients who transitioned to ASCT while in the chronic phase of the disease (Group A) displayed superior post-transplant survival (PTS) compared to those who underwent ASCT after blast transformation (Group B). In Group A, patients who received ASCT had a median post-transplant survival of 95 months, while those in Group B had a median post-transplant survival of only 16 months.

Key Takeaways:

  • Patients who transitioned to ASCT while in the chronic phase of CMML (Group A) had superior post-transplant survival compared to those who underwent ASCT after blast transformation (Group B).
  • The median post-transplant survival for patients in Group A was 95 months, while those in Group B had a median post-transplant survival of only 16 months.
  • The observed detrimental impact of post-transplant cyclophosphamide (PTCy) on post-transplant survival requires additional studies to confirm and investigate the underlying mechanisms.
  • The study retrospectively analyzed 138 CMML patients who underwent ASCT at the Mayo Clinic.
  • The research team, led by Estefania Gauto Mariotti, analyzed patient data to identify risk factors and post-transplant outcomes.
  • The study's findings suggest that allogeneic stem cell transplantation is a potential curative option for CMML patients.

Statistics:

  • Median post-transplant survival for patients in Group A: 95 months
  • Median post-transplant survival for patients in Group B: 16 months
  • Total number of patients analyzed: 138
  • Patients in Group A: xx (exact number not provided)
  • Patients in Group B: xx (exact number not provided)
  • Post-transplant cyclophosphamide (PTCy) patients: xx (exact number not provided)

Sources:

  • Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients. Blood Cancer Journal, 2025;15(1):157.
  • Estefania Gauto Mariotti, Division of Hematology, Mayo Clinic, Rochester, MN, United States.
  • Springernature, Campus, 4 Crinan St, London, N1 9XW, England. (Nature Publishing Group - www.nature.com/; Blood Cancer Journal - www.nature.com/bcj/)
  • NewsRx. Mayo Clinic Describes Findings in Chronic Myelomonocytic Leukemia (Allogeneic stem cell transplantation in chronic myelomonocytic leukemia: analysis of post-transplant survival and risk factors in 138 Mayo Clinic patients). Hematology Week. October 20, 2025; p 802.